Lupus erythematosus

This phase 2 trial is testing whether a single infusion of a patient's own genetically modified immune cells, called C-CAR168, can safely and effectively treat lupus nephritis that has not responded to standard therapies. The cells are designed to target and eliminate specific im…

This early study tests a new drug called HN2302, which aims to create CAR-T cells inside the body to target and control autoimmune diseases like lupus and scleroderma. The trial will enroll 12 adults to check safety and see if the treatment works. It is a first step, so results w…

This trial tests whether an experimental drug called ESG206 can safely reduce disease activity in adults with systemic lupus erythematosus (SLE). Participants will receive either ESG206 or a placebo, and researchers will measure how many achieve a meaningful improvement in lupus …

This trial is testing whether anifrolumab, an experimental antibody, can help Chinese adults with moderate-to-severe systemic lupus erythematosus (SLE) achieve remission. Participants receive anifrolumab infusions over 52 weeks alongside standard care, with a focus on safely redu…

This early-stage trial is evaluating an investigational drug called QLS2404, given as an injection, to see if it is safe and tolerable. The study first tests single doses in healthy volunteers, then moves to multiple doses in people with systemic lupus erythematosus or primary Sj…

This early-phase trial is testing an investigational drug called ACG102, given by intravenous infusion, in people with refractory active systemic lupus erythematosus (SLE) — a form of lupus that has not responded well to standard treatments. The main goals are to check the drug's…

This early-stage trial is testing an experimental drug called SNC116 in people with refractory systemic lupus erythematosus (SLE), a form of lupus that hasn't improved with standard treatments. The study aims to see if a single intravenous infusion of SNC116 is safe and tolerable…

This phase 1 trial tests an experimental cell therapy called LMY-922 (BAFF CAR-T cells) in people aged 16 to 75 with refractory autoimmune diseases, including rheumatoid arthritis, lupus, dermatomyositis, and systemic sclerosis. The therapy uses donor immune cells engineered to t…

This phase 1 trial is testing an experimental drug called ATG-201 in adults with systemic lupus erythematosus, systemic sclerosis, or Sjögren's disease. ATG-201 is designed to bind to specific proteins on immune cells, potentially quieting the overactive immune response that driv…

This phase II trial tests whether obinutuzumab, a B-cell targeting antibody, can alone achieve complete kidney response in people with pure class V lupus nephritis—a form of lupus kidney disease with no approved treatments. Participants receive up to four infusions over seven mon…

This study tests whether taking high-dose omega-3 (fish oil) pills for 12 weeks can reduce inflammation and cell damage in women with lupus who are in remission. Researchers will measure changes in blood markers and telomere length, which is linked to aging. The goal is to see if…

This early-phase trial tests a single dose of universal (off-the-shelf) CAR-T cells in 30 adults with active autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's. The treatment targets CD19 and BCMA on immune cells to reset the faulty immune system. The…

This study offers continued access to anifrolumab (Saphnelo) for people with systemic lupus erythematosus, systemic sclerosis, or myopathies who completed a prior anifrolumab trial and are still benefiting from the drug. Participants receive the same treatment as before, while re…

This study tests anifrolumab, a drug for systemic lupus erythematosus (SLE), given either as a shot under the skin or through an IV. The goal is to see how the body processes the drug and check its safety. About 92 adults with lupus will take part.

This early-stage study is testing a new treatment called C-CAR168 for people with autoimmune diseases like multiple sclerosis, lupus, and myasthenia gravis that have not improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab…

This early-phase trial tests a single infusion of universal CAR-T cells (RD06-05) in 30 children and adolescents with severe autoimmune diseases, including lupus, scleroderma, and kidney inflammation. The cells are designed to target and calm overactive immune cells. The main goa…

This trial tests a one-time treatment called CAR-T cell therapy for people with systemic lupus erythematosus (lupus) that hasn't improved with standard medications. The therapy uses a patient's own immune cells, which are modified in a lab to find and destroy the B cells that dri…

This early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. …

This study tests whether teprenone, a stomach-protecting drug, can reduce gastrointestinal damage caused by high-dose steroids in people with lupus. One hundred participants will be randomly assigned to take either teprenone or the standard acid-blocker omeprazole for 12 weeks. T…

This first-in-human study tests the safety of a new drug called HBM7020. It will first be given to healthy volunteers at low doses, then to people with moderate to severe autoimmune diseases like lupus, rheumatoid arthritis, scleroderma, and Sjögren's disease. The goal is to see …

This early-stage trial tests a one-time infusion of donor immune cells (CAR-γδT cells) designed to target and destroy faulty B cells in people with severe autoimmune diseases like lupus and scleroderma. The main goal is to check safety and find the right dose in 9 adults whose di…

This study tests anifrolumab, a drug already used in adults with lupus, in children aged 5 to 17. The goal is to see how the drug moves through the body and if it is safe. Twenty-four children with moderate to severe lupus will receive the drug as a shot under the skin, while con…

This early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants recei…

This early study tests a new drug called STR-P005 in 18 people with autoimmune diseases that have not responded to standard treatments. The main goal is to check safety and find the best dose. Participants receive the drug by infusion in different schedules, and researchers will …

This early study tests a new drug called MTM-H-001 in 75 adults with B-cell-related autoimmune diseases, including lupus, multiple sclerosis, and rheumatoid arthritis. The main goal is to check safety and find the right dose. Participants receive the drug by injection, and resear…

This early-stage study tests a new treatment called LVIVO-TaVec400 in 44 people with severe autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis that have not responded to standard therapies. The main goals are to check the treatment's safety and find the rig…

This study tests whether dihydroartemisinin, a drug used for malaria, can help treat discoid lupus erythematosus (DLE), a chronic skin condition causing red, scaly patches. Researchers will compare two doses of the drug to a standard lupus treatment (hydroxychloroquine) in 100 ad…

This study tests whether a Mediterranean diet can improve gut bacteria, reduce disease activity, and boost nutrition in children with systemic lupus erythematosus (SLE). Sixty children with SLE and their healthy family members will take part. Participants will receive personalize…

This early-stage study tests whether a single infusion of a patient's own modified immune cells (CAR-T cells) is safe for people with severe autoimmune diseases like lupus, rheumatoid arthritis, or scleroderma that haven't improved with standard treatments. Only 6 adults aged 18-…

This study tests a new medicine, SCTC21C, in 159 adults with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The goal is to see if the drug is safe and can reduce lupus symptoms. Participants must be on stable standard treatments and will receive the study drug …

This early-stage trial is testing a new drug called YKST02, given alone or with another drug YK012, in 30 people with active or hard-to-treat lupus. The main goal is to see if the drugs are safe and tolerable. Participants will receive intravenous infusions and be monitored for a…

This study tests whether regularly measuring the amount of mycophenolate mofetil in the blood helps more people with lupus kidney disease achieve kidney remission. One hundred adults with active lupus nephritis will be split into two groups: one gets standard dosing, the other ge…

This early-stage trial will test a new cell therapy called YTS109 in 12 children aged 5 to 17 with severe autoimmune diseases like lupus or scleroderma that have not responded to standard treatments. The children will receive a single infusion of these cells, and researchers will…

This early-phase study tests a new mRNA drug that targets two proteins (CD19 and BCMA) on immune cells. The goal is to clear the faulty B cells and plasma cells that attack the body in autoimmune diseases. 27 adults aged 18-70 with relapsed or hard-to-treat autoimmune diseases wi…

This study compares two drugs, telitacicept and belimumab, for controlling systemic lupus erythematosus (SLE) in adults aged 18-65. Participants choose their treatment with their doctor, and researchers track how well each drug reduces lupus activity and kidney problems. The goal…

This early-stage study tests a new medicine called HC022 in 32 adults with lupus (SLE or CLE). The main goal is to see if the drug is safe and how the body handles it. Participants will receive multiple doses or a placebo, and researchers will monitor for side effects and measure…

This early study tests a new drug called STR-P004 in 9 adults with immune-mediated kidney diseases. The goal is to see if the drug is safe and how the body processes it. Participants receive up to 8 infusions over 28 days, with possible dose increases. This is not a cure; it aims…

This early-phase study tests a new mRNA therapy that targets CD19, a protein on immune cells, to treat autoimmune diseases like lupus and immune anemia. The treatment uses lipid nanoparticles to deliver mRNA that helps the body clear harmful B cells. About 47 participants aged 14…

This early-phase trial is testing a new treatment called CRC01 for people with severe lupus nephritis, a serious kidney complication of lupus. The therapy uses a patient's own immune cells, which are modified in a lab to target and destroy certain immune cells that drive the dise…

This early-phase study tests a new drug called WGb-0301 for people with autoimmune diseases (like lupus or autoimmune hepatitis) that haven't responded to standard treatments. The drug uses mRNA technology to target and clear certain immune cells (B cells) that are causing the di…

This early-stage trial tests a new treatment called KN5501 for people with moderate to severe lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) to target and destroy faulty B cells that drive the disease. Partic…

This early-phase trial tests a new type of cell therapy called BCMA-CD19-IL-15/IL15sushi compound CAR T cells in 20 people with severe lupus that hasn't improved with standard treatments. The therapy aims to reset the immune system by targeting and eliminating faulty immune cells…

This early-stage trial is testing a new treatment called ACE1831 for people with lupus that has not responded to standard therapies. ACE1831 is made from healthy donor immune cells and is given after a short course of chemotherapy. The study will enroll 22 adults aged 18 to 60 wi…

This early-phase trial will test BCT301, a type of immune cell made from stem cells, in 10 people with severe autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these cells after a short course of chemotherapy. The main goal is to check safe…

This early study tests a new treatment called CD19 UCAR-T cells for people with autoimmune diseases like lupus, vasculitis, and Sjögren's syndrome. The therapy uses modified immune cells to target and calm the overactive immune system. The main goals are to check safety and see i…

This early-phase study tests a new treatment called CD19/BCMA CAR-T cell therapy for adults with refractory systemic lupus erythematosus (SLE) that hasn't improved with standard treatments. About 24 participants will receive a single infusion of their own engineered immune cells …

This study tests whether a low-gluten diet, tailored to a person's genetic makeup, can help manage systemic lupus erythematosus (SLE). Researchers will screen 100 lupus patients for specific genes (HLA-DQ2 or DQ8) and then randomly assign those who test positive to either a low-g…

This study tests a new treatment using CD19 CAR T-cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 30 participants will receive a single dose of these engineered immune cells after chemotherapy. The goal is to see if it's safe …

This study is testing whether a pill called enpatoran can safely reduce active skin rashes in people with lupus. About 202 participants with moderate-to-severe lupus skin symptoms will take either enpatoran or a placebo pill for 24 weeks, while continuing their standard lupus med…

This study asks whether levels of uromodulin, a protein in the blood, can indicate the severity of kidney damage in people with lupus nephritis. Researchers will compare uromodulin levels with kidney biopsy results from 90 participants, including those with different classes of l…

This study investigates whether levels of a protein called RNASE1 in the blood can serve as a biomarker for lupus nephritis, a serious kidney complication of systemic lupus erythematosus (SLE). Researchers will compare RNASE1 levels in 128 adults with SLE, some with lupus nephrit…

Lupus nephritis is a serious kidney complication of lupus that can lead to kidney failure. This study investigates whether levels of neutrophil extracellular traps (NETs)—web-like structures released by immune cells—in the blood can predict how well patients respond to therapy. R…

This study tests whether a single dose of amoxicillin before a simple tooth extraction can prevent infections in people with autoimmune rheumatic diseases who are on immune-suppressing medications. Researchers will compare infection rates between those who get the antibiotic and …

This trial investigates whether annual re-screening for tuberculosis infection using a blood test (IGRA) can prevent active TB in people with autoimmune rheumatic diseases who are taking biologic or immunosuppressive medications. Participants who initially test negative for TB ar…

This trial investigates whether taking melatonin before bed can improve sleep quality, reduce fatigue, and lower inflammation in adults with active lupus. Sixty-four participants will either receive standard care plus melatonin or standard care alone for 12 weeks. Researchers wil…

This study tests whether a 16-week personalized home exercise program can improve muscle health and reduce fatigue in adults with stable lupus. Participants do three weekly sessions combining high-intensity interval training, strength exercises, and walking. Researchers measure c…

This study looks at whether a 12-session weekly yoga program, added to usual medical care, can help adults with systemic autoimmune and inflammatory diseases (like lupus) feel less tired, have less pain, and improve their mood. Researchers will also check if yoga helps people sti…

This study looks at whether a 12-week aerobic exercise program can improve thinking skills and reduce disease activity in people with lupus. Researchers will test memory, attention, and walking ability before and after the program. The goal is to see if exercise can ease lupus-re…

This study tests a new online program called TEAM-LEADS designed to help teens and young adults (ages 13-22) with lupus or dermatomyositis reduce stress and improve heart-healthy behaviors like diet, exercise, and sleep. The program is self-guided and completed online. The study …

This study tests whether hypnotherapy can reduce pain and anxiety in children aged 6 to 18 during needle procedures like injections or blood draws. About 70 kids with conditions like juvenile arthritis or lupus will be randomly assigned to receive either hypnotherapy or standard …

This study is building a biobank of blood samples and imaging data from 300 people with suspected inflammatory heart or autoimmune rheumatic diseases. Researchers aim to identify immune biomarkers that could predict major heart events like heart failure, stroke, or atrial fibrill…

This early-stage trial is testing a single injection of an experimental drug called SHR-7012 in healthy adults. The main goal is to check how safe and tolerable the drug is, and how the body absorbs and processes it. The study involves about 50 participants aged 18 to 55, who wil…

This study investigates whether the triglyceride-glucose (TyG) index, a simple blood-based measure of insulin resistance, can predict early signs of atherosclerosis in people with lupus nephritis. Researchers will measure carotid artery thickness and plaque in 156 adults with lup…

This study looks at children with immune thrombocytopenic purpura (ITP) who also have certain antibodies, as they are at higher risk of developing lupus. Researchers will analyze blood samples to track immune cell changes and markers that may signal the transition to lupus. The g…

This study investigates whether a specific gene variation (ICOS) is linked to developing systemic lupus erythematosus (SLE) and how severe the disease becomes. Researchers will analyze blood samples from 30 people diagnosed with SLE to look for patterns in the ICOS gene. The goal…

This study aims to find out which daily habits and surroundings are linked to poor sleep in people with lupus. Researchers will survey 250 adults with lupus from different parts of Spain about their sleep, physical activity, screen time, and bedroom environment. The goal is to id…

This study looks at whether two substances in the blood, IL-6 and MMP-7, can help doctors diagnose and predict the course of a rare lung disease in children. Researchers will measure these markers in 60 children with immune-mediated interstitial lung disease and compare them to h…

This study looks at 70 children and teens with juvenile lupus to check for early signs of heart disease using an ultrasound of the neck artery. Researchers will see if things like cholesterol, blood pressure, and lupus activity are linked to artery thickness. No treatment is give…

This observational study will enroll 1,000 pregnant women and their fetuses to establish normal ranges for heart sounds and ECGs. The goal is to develop early warning systems for serious heart events in mothers, progression of fetal heart defects, and autoimmune-related fetal hea…

This early-stage trial is the first time ISH0613 will be given to humans. It aims to check the drug's safety and how it moves through the body in 26 healthy Chinese adults. Participants receive a single intravenous dose of either ISH0613 or a placebo and are closely monitored for…

This study will look at how the lupus medication Saphnelo (anifrolumab) is being used in women aged 15 to 50 who could become pregnant. Researchers will track how many women use the drug each year and describe their health characteristics. The goal is to gather real-world informa…

This study will follow 1,500 people with lupus or other autoimmune diseases to see if advanced heart scans can predict heart attacks, strokes, or other heart problems. Participants will have one of three types of heart imaging. The goal is to learn if these scans can help doctors…

This early-stage study will test the safety and tolerability of a new drug called ACT100 in 48 healthy adults. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure how the drug moves through the body. This is the first …

This study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …

This study looks at 400 people with lupus to compare those with typical symptoms versus those with unusual or 'atypical' symptoms. The goal is to understand how these differences affect disease activity, organ damage, and treatment needs over time. By identifying these patterns, …

This study looks at two genes (IL-1β and IL-33) in 300 adults with low platelet counts caused by either primary immune thrombocytopenia (ITP) or lupus (SLE). Researchers will measure gene activity from a blood sample to see if these genes can help tell the two conditions apart. T…

This study aims to better understand why some people's immune cells attack their own body, causing autoimmune diseases like lupus and scleroderma. Researchers will analyze blood samples from 200 adults with these conditions to identify and measure specific harmful immune cells. T…

This study looks at two substances in the blood—microRNA-101-3p and autotaxin—in 40 adults with lupus and 40 healthy volunteers. Researchers want to see if these markers are different in people with lupus and if they are linked to how active the disease is. No treatments or drugs…

This study follows 700 adults recently diagnosed with lupus across Europe for up to 5 years. Researchers will track symptoms, treatment, and quality of life, and collect blood and urine samples. The goal is to understand how lupus develops early on and find markers that predict w…

This study will use a special blood test called mass spectrometry to look at immune cells in 500 people with various autoimmune diseases and healthy volunteers. The goal is to find patterns that could help doctors diagnose these conditions sooner. No treatments are being tested; …

The LUNET project is creating a registry of 1,500 Italian adults with systemic lupus erythematosus (SLE). By collecting real-world data from clinics across Italy, researchers hope to better understand the disease and improve how it is managed in daily practice. This is an observa…

This study will collect health information, samples, and data from 100 people in Luxembourg (800 total across Europe) who have rheumatoid diseases and are starting or changing treatment. Researchers hope to find patterns that can predict which treatments work best for each person…

This observational study will check if having an H. pylori stomach infection is linked to more active lupus in 115 adults. Researchers will use a stool test to detect the bacteria and a standard lupus score to measure disease activity. No treatments are given; the goal is simply …

This study will measure levels of a protein called IL-33 in the blood of 150 people: lupus patients with kidney inflammation, lupus patients without kidney issues, and healthy volunteers. Researchers want to see if higher IL-33 levels are linked to more severe disease, especially…